| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | Jan 15, 2025 | 1 | $0 | 4 | Jan 17, 2025 | Chief Financial Officer |
| SYRE | Spyre Therapeutics, Inc. | Sep 3, 2024 | 1 | -$522K | 4 | Sep 5, 2024 | Chief Financial Officer |
| SYRE | Spyre Therapeutics, Inc. | Feb 1, 2024 | 1 | $0 | 4 | Feb 2, 2024 | Chief Financial Officer |
| SYRE | Spyre Therapeutics, Inc. | Dec 22, 2023 | 1 | $0 | 4 | Dec 22, 2023 | Chief Financial Officer |
| AGLE | Aeglea BioTherapeutics, Inc. | Sep 1, 2023 | 1 | $0 | 4 | Sep 5, 2023 | Chief Financial Officer |
| AGLE | Aeglea BioTherapeutics, Inc. | Sep 1, 2023 | 0 | $0 | 3 | Sep 5, 2023 | Chief Financial Officer |
| ARQT | Arcutis Biotherapeutics, Inc. | Mar 6, 2023 | 1 | -$4.44K | 4 | Mar 8, 2023 | Chief Financial Officer |
| ARQT | Arcutis Biotherapeutics, Inc. | Mar 2, 2023 | 2 | $0 | 4 | Mar 6, 2023 | Chief Financial Officer |
| ARQT | Arcutis Biotherapeutics, Inc. | Feb 28, 2023 | 3 | -$29.4K | 4 | Mar 2, 2023 | Chief Financial Officer |
| ARQT | Arcutis Biotherapeutics, Inc. | Sep 16, 2022 | 2 | $8.4K | 4 | Sep 20, 2022 | Chief Financial Officer |
| ARQT | Arcutis Biotherapeutics, Inc. | Mar 3, 2022 | 4 | -$5.1K | 4 | Mar 7, 2022 | Chief Financial Officer |
| ARQT | Arcutis Biotherapeutics, Inc. | Mar 1, 2022 | 1 | -$7.46K | 4 | Mar 3, 2022 | Chief Financial Officer |
| ARQT | Arcutis Biotherapeutics, Inc. | Dec 30, 2021 | 1 | $0 | 4 | Jan 4, 2022 | Chief Financial Officer |
| ARQT | Arcutis Biotherapeutics, Inc. | Dec 27, 2021 | 1 | -$252K | 4 | Dec 28, 2021 | Chief Financial Officer |